Synthetic Biology (SynBio) in Drug Discovery and Next-generation Therapeutics

Synthetic Biology (SynBio) in Drug Discovery and Next-generation Therapeutics

Disruptive Technology Advances in SynBio Foster a Thriving Stakeholder Ecosystem and Accelerate Biopharma Developments

RELEASE DATE
29-Jun-2023
REGION
Global
Research Code: DAA1-01-00-00-00
SKU: HC03683-GL-TR_27821
AvailableYesPDF Download
$4,950.00
In stock
SKU
HC03683-GL-TR_27821
$4,950.00
DownloadLink
ENQUIRE NOW

Description

The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening and easing drug discovery. Its contribution to therapeutics has resulted in the design and development of more sustainable and stable therapies. Emerging and promising SynBio tools, such as gene circuits and CRISPR systems, enable the development of next-generation cell therapies, antibodies, and engineered organisms with therapeutic effects. The rise in next-generation therapeutics will be evident in the coming years, especially in developing CAR-T cell immunotherapy using Synbio, as it can provide accuracy and personalization.

Frost & Sullivan notes a rise in the SynBio start-up ecosystem across regions as the world moves toward precision medicine. Intense R&D efforts are ongoing in academia, start-ups, and big pharmaceutical companies toward developing SynBio-driven therapies for cancer, infectious diseases, and rare diseases.

Therapeutics biomanufacturing also widely uses SynBio platforms, allowing companies to scale therapeutics based on commercial requirements cost-efficiently. Technology developments will boost the global adoption of SynBio tools, encourage the funding ecosystems, and move toward high-growth opportunities.

Information provided in this report includes the following:
•     Growth drivers and restraints (2023–2027)
•     Developments in SynBio technologies supporting drug discovery
•     Critical challenges in developing SynBio therapeutics and the steps taken to address them
•     Global market participants with potential

Table of Contents

Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on SynBio in the Drug Discovery and Therapeutics Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Research Methodology

SynBio Emerges as a Promising Tool in R&D

Growth Drivers

Growth Restraints

Scope of Analysis

Segmentation

Technology Maturity

Emerging Companies, 2020–2022

Trends

Key Findings

Gene Circuits and CRISPR Systems Identify Novel Targets

SynBio Platforms Accelerate the Design and Development of Advanced Therapeutics

Role of SynBio Approaches in the Drug Discovery Pipeline

Target Identification and Drug Molecule Screening Using SynBio-driven Approaches

Advanced CRISPR Systems for Improved Drug Target Screening

Complex Gene Circuits Act as a Tool for Real-time Monitoring of Drug Discovery

Advanced Synthetic Circuit Platforms Enable High-throughput Drug Screening and Selection

Organ-on-a-chip and Organoid Systems Speed SynBio-driven Drug Discovery

Improving the Design of SynBio Tools to Address Challenges in Drug Discovery

The Growing Network of SynBio-driven Drug Discovery Companies

Developing Next-generation Therapeutics Using SynBio Tools

Controlled Therapeutic Responses Achieved Using SynBio Tools

SynBio Platform Adoption Can Transform Global Disease Treatment

Developing Advanced Therapeutics and Vaccines with SynBio Tools

Industry Players Developing Advanced Therapeutics and Vaccines Using SynBio Tools

SynBio Tools Enable the Development of Smart Cell Therapies

Logic Gates Improve the Engineered Cellular Activity with a Precise Switch On/Off Mechanism

R&D Efforts Focus on Developing Suitable SynBio Circuit/System

R&D Players Developing Programmable Medicine Using Gene Circuits

Multifunctional Chassis Organisms Used as Therapeutics Improve Scalability and Delivery

Developing Synthetically Engineered Microbiome Therapies

Engineered Microorganisms n Functioning as Live Therapeutics

Biosensors Identify Drug Targets and Release Therapeutics with Sensitivity

Cell-free Biomanufacturing of Therapeutics Using Gene Circuits

Growing Applications and Demand for Cell-free Biomanufacturing Systems

Encouraging Global Funding Activities to Boost the Growth f SynBio Platforms

Growing Mergers & Acquisitions o Improve SynBio Platform Capabilities

Growing Partnerships Between SynBio Therapy Developers and Pharmaceutical Companies

Global SynBioPlatforms or Accelerated Drug Discovery and Therapeutics

Gap Analysis for SynBio-based Therapies

Gap Analysis for SynBio-based Therapies (continued)

Living ell Therapeutics to Release Therapies Based on Gene Circuits

Growth Opportunity 1: Improve the Long-term Efficiency of CAR-T Cell Therapies Using Synthetic Gene Circuits

Growth Opportunity 1: Improve the Long-term Efficiency of CAR-T Cell Therapies Using Synthetic Gene Circuits (continued)

Growth Opportunity 2: Foster Collaborations to Build Convergent SynBio Platforms

Growth Opportunity 2: Foster Collaborations to Build Convergent SynBio Platforms (continued)

Growth Opportunity 3: Streamline Regulatory Pathways for Using Synthetic Gene Circuits in Therapeutics

Growth Opportunity 3: Streamline Regulatory Pathways for Using Synthetic Gene Circuits in Therapeutics (continued)

Advanced SynBio DBTL Cycle Speeds Drug Discovery

Your Next Steps

Why Frost, Why Now?

Legal Disclaimer

The SynBio field has evolved well over the past two decades, with significant technology disruptions leading to new opportunities and remarkable growth potential. Advances in SynBio technologies have transformed drug discovery and therapeutics development, accelerating the identification of novel drug targets and high-throughput compound screening and easing drug discovery. Its contribution to therapeutics has resulted in the design and development of more sustainable and stable therapies. Emerging and promising SynBio tools, such as gene circuits and CRISPR systems, enable the development of next-generation cell therapies, antibodies, and engineered organisms with therapeutic effects. The rise in next-generation therapeutics will be evident in the coming years, especially in developing CAR-T cell immunotherapy using Synbio, as it can provide accuracy and personalization. Frost & Sullivan notes a rise in the SynBio start-up ecosystem across regions as the world moves toward precision medicine. Intense R&D efforts are ongoing in academia, start-ups, and big pharmaceutical companies toward developing SynBio-driven therapies for cancer, infectious diseases, and rare diseases. Therapeutics biomanufacturing also widely uses SynBio platforms, allowing companies to scale therapeutics based on commercial requirements cost-efficiently. Technology developments will boost the global adoption of SynBio tools, encourage the funding ecosystems, and move toward high-growth opportunities. Information provided in this report includes the following: • Growth drivers and restraints (2023–2027) • Developments in SynBio technologies supporting drug discovery • Critical challenges in developing SynBio therapeutics and the steps taken to address them • Global market participants with potential
More Information
Author Neeraja Vettekudath
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 synthetic biology
Keyword 2 drug development research
Keyword 3 new drug discovery
Podcast No
WIP Number DAA1-01-00-00-00